Why Allarity Therapeutics (ALLR) Stock Is Getting Hammered

Zinger Key Points
  • Allarity Therapeutics shares are trading lower by 27.6% during Monday's session.
  • The company announces it received a noncompliance letter from the Nasdaq.

Allarity Therapeutics Inc ALLR shares are trading lower by 28.40% to $0.32 during Monday’s session after the company announced it received a noncompliance letter from the Nasdaq.

On June 18, Allarity received a notice from Nasdaq indicating the company failed to meet the requirement of maintaining a minimum bid price of $1 per share for 30 consecutive business days. Allarity plans to request a hearing to appeal for continued listing.

This request will temporarily prevent the suspension and delisting of its stock until the hearing concludes. However, there is no guarantee that the appeal will be successful and that the company’s stock will continue to be listed on the Nasdaq Capital Market.

According to data from Benzinga Pro, ALLR has a 52-week high of $269.80 and a 52-week low of $0.32.

See Also: ‘Stock Market Has A Bad Breadth Problem Again,’ Veteran Wall Street Investor Warns

Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareMarketsMoversNASDAQwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!